Hays Advisory’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Hays Advisory’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-95,710	Closed	-$4.8M	–	85
2016 Q4	$4.8M	Sell	95,710 -27,438	-22%	-$1.44M	1.07%	26
2016 Q3	$6.46M	Sell	123,148 -12,574	-9%	-$600K	1.08%	24
2016 Q2	$5.61M	Buy	+135,722	New	+$5.9M	0.87%	29

Other funds holding FPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Hays Advisory's FPRX Position: Q1 2017 in Review

Hays Advisory sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2017, closing a stake of 95,710 shares — an estimated $4.8M sold.

Hays Advisory first reported a position in FPRX in Q2 2016 and held it in 3 quarters. The position peaked at $6.46M in Q3 2016. 157 funds tracked by Wall St. Rank hold FPRX as of Q1 2017.

Hays Advisory reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
Hays Advisory sold 95,710 Five Prime Therapeutics, Inc. shares in Q1 2017, an estimated $4.8M.
Hays Advisory first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 3 quarters.
Hays Advisory's Five Prime Therapeutics, Inc. position peaked at $6.46M in Q3 2016.
157 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2017.

Based on Hays Advisory's 13F filing for Q1 2017, filed 13 Apr 2017.